

DECISIONS WITHOUT A SIGNIFICANT FINANCIAL OR COMMISSIONING IMPACT (decisions approved on medicines committee ICB directors' authority)					
NICE Technology Appraisal/Guidance/Drug	Date published	Current formulary status or pathway/guidance relevance	Recommendation	Commissioning & financial implications	Decision
<p><a href="#">TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction</a></p> <p><b>Commissioning: ICS</b></p> <p>Empagliflozin is recommended, within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. If people with the condition and their clinicians consider empagliflozin to be 1 of a range of suitable treatments (including dapagliflozin), after discussing the advantages and disadvantages of all the options, use the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.</p>	01/11/2023	<p>GREEN drug for type 2 diabetes</p> <p>GREEN+ drug for the treatment of chronic heart failure with reduced ejection fraction in adults in line with NICE TA773.</p>	Add to formulary as a GREEN+ drug in this indication with a link to TA929.	<p>Empagliflozin has been recommended through the NICE cost comparison process, NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication.</p> <p>A cost comparison suggests empagliflozin has similar costs to dapagliflozin. So, empagliflozin is recommended. Empagliflozin should be started on the advice of a heart failure specialist.</p> <p>The list price of 10 mg empagliflozin is £36.59 per 28-tablet pack (excluding VAT; BNF online accessed August 2023). The annual treatment cost is £477.30.</p>	Approved by NENC ICB Chief Pharmacist 20.11.23.

Key for Recommended RAG status: Not Approved (DNP), Green – suitable for prescribing in primary care; Green+ Specialist Initiation/Recommendation – should be started or recommended by a specialist but suitable for ongoing prescribing in primary care; Shared Care – suitable for prescribing under an agreed shared care protocol; or Red – not suitable for prescribing in primary care.